Ftse Mib
34.186,18
0,07%
DAX
19.909,14
-0,25%
S&P 500
5.881,63
-0,43%
NASDAQ
19.310,79
-0,90%
Bitcoin
94.942,00
0,58%
Pepperstone
Advertisement
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Arbutus Biopharma Corporation (ABUS) Arbutus Biopharma Corporation (ABUS) Notizie

Arbutus Biopharma Corporation

ABUS
3,2988
0,0988 (3,09%)
01 Gen 2025 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
06/12/202406:15EDGAR2Form EFFECT - Notice of Effectiveness
03/12/202414:00BWWhitefort Capital Sends Letter to Arbutus Biopharma Board of..
26/11/202413:30GLOBEArbutus to Participate in H.C Wainwright @ Home Virtual..
15/11/202417:03EDGAR2Form 8-K - Current report
15/11/202417:02GLOBEArbutus’ Imdusiran Achieves Functional Cure in cHBV Patients..
14/11/202414:41EDGAR2Form SC 13G/A - Statement of Beneficial Ownership by Certain..
14/11/202413:30GLOBEArbutus to Present at Jefferies London Healthcare Conference
06/11/202422:53EDGAR2Form S-3 - Registration statement under Securities Act of..
06/11/202422:02EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
06/11/202413:31EDGAR2Form 8-K - Current report
06/11/202413:30GLOBEArbutus Reports Third Quarter 2024 Financial Results and..
23/10/202413:30GLOBEArbutus to Report Third Quarter 2024 Financial Results and..
15/10/202414:26EDGAR2Form 8-K - Current report
15/10/202414:16GLOBEArbutus Announces Multiple Abstracts Highlighting Imdusiran..
11/10/202422:07EDGAR2Form 8-K - Current report
01/10/202413:30GLOBEArbutus to Present at H.C. Wainwright 5th Annual Viral..
03/9/202413:30GLOBEArbutus to Participate in Two Upcoming Investor Conferences
08/8/202422:17EDGAR2Form S-8 - Securities to be offered to employees in employee..
05/8/202422:13EDGAR2Form 8-K - Current report
01/8/202413:31EDGAR2Form 8-K - Current report
01/8/202413:30GLOBEArbutus Reports Second Quarter 2024 Financial Results and..
18/7/202413:30GLOBEArbutus to Report Second Quarter 2024 Financial Results and..
06/6/202417:16EDGAR2Form 8-K - Current report
06/6/202417:15GLOBETreatment with Arbutus’ Imdusiran and VTP-300 Achieves..
05/6/202412:00EDGAR2Form 8-K - Current report
05/6/202408:30GLOBEArbutus’ Imdusiran with Short Course Interferon Achieves..
29/5/202413:30GLOBEArbutus to Participate in Jefferies Global Healthcare..
28/5/202422:25EDGAR2Form 8-K - Current report
24/5/202422:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/5/202422:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/5/202412:00EDGAR2Form 8-K - Current report
22/5/202408:00GLOBEArbutus to Present Imdusiran Data at EASL Congress 2024
17/5/202415:03EDGAR2Form SC 13D/A - General statement of acquisition of..
17/5/202415:00BWWhitefort Capital Publishes Open Letter to Arbutus Biopharma..
09/5/202414:00EDGAR2Form SC 13D - General statement of acquisition of beneficial..
07/5/202413:30GLOBEArbutus to Participate in Two Upcoming Investor Conferences
02/5/202413:30GLOBEArbutus Reports First Quarter 2024 Financial Results and..
02/5/202413:25GLOBEArbutus Announces Retirement of Chief Scientific Officer,..
18/4/202413:30GLOBEArbutus to Report First Quarter 2024 Financial Results and..
04/4/202414:30GLOBEArbutus Biopharma Announces Claim Construction Ruling in its..
08/3/202413:30GLOBEArbutus to Participate in Two Upcoming Investor Conferences
05/3/202422:48EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
29/2/202413:31EDGAR2Form 8-K - Current report
29/2/202413:30GLOBEArbutus Reports Fourth Quarter and Year End 2023 Financial..
15/2/202413:30GLOBEArbutus to Report Fourth Quarter and Year End 2023 Financial..
14/2/202422:38EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202416:48EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
06/2/202401:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/2/202401:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/2/202401:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
Apertura: 3,24 Min: 3,21 Max: 3,285
Chiusura: 3,20

La tua Cronologia

NASDAQ
ABUS
Arbutus Biopharma
NASDAQI
OMXHCAPPI
OMX Helsinki Cap PI
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network